Program
KYLO-0603
A development code. Also written as “Kylo 0603 Capsule 8mg”, “Kylo 0603 Capsule 12mg” and “Kylo 0603 Capsule 16mg”.
In Sino Biopharmaceutical's pipeline, THR-β激动剂
. Its studies are mostly in Non-alcoholic Fatty Liver Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kylonova (Xiamen) Biopharma | 10 open or running | phase 1since Apr 10, 2024 | Apr 10, 2024 | none ahead |
| Sino Biopharmaceutical | 11 open or running | phase 2since Sep 24, 2026 | Sep 24, 2026 | Aug 15, 2027phase 2 · NCT07878091 |
- Named in Sino Biopharmaceutical’s own pipeline as
Kylo-0603
, phase 1, as of Nov 16, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2024First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseNew to Kylonova (Xiamen) BiopharmaKylonova (Xiamen) Biopharma · NCT06365580 · 132 enrolled · China
- Sep 24, 2026Sino Biopharmaceutical's first study: phase 2 study in Metabolic Dysfunction-Associated Steatoic Liver DiseaseNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT07878091 · 120 planned · China
Ahead
- Aug 15, 2027Primary completion: phase 2 study in Metabolic Dysfunction-Associated Steatoic Liver DiseaseSino Biopharmaceutical · NCT07878091
TargetBeta
“THR-β激动剂”the company's pipeline, read by Claude · source
Other programs on THRB
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| resmetiromrule | Madrigal Pharmaceuticals | phase 4 | 22 |
| CG-0416rule | hongkong-curegene-innovation-co-limited | phase 1 | 1 |
| KPC000154rule | kunming-pharmaceuticals-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07878091Metabolic Dysfunction-Associated Steatoic Liver Disease · China | 2 | Not yet recruiting | Sino Biopharmaceutical | Aug 15, 2027 | 120 |
| NCT06365580Non-alcoholic Fatty Liver Disease · China | 1 | Completed | Kylonova (Xiamen) Biopharma | Aug 16, 2024 | 132 |
How it is read
Names in the registry
- “Kylo 0603 Capsule 8mg”, 1 entry
- “Kylo 0603 Capsule 12mg”, 1 entry
- “Kylo 0603 Capsule 16mg”, 1 entry
- “Kylo-0603 capsule”, 1 entry
Codes read as this program: KYLO0603.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.